Astrazeneca

(Image: Getty/Bong Hyunjung)

MedImmune will cease to exist after 30 years

By Ben Hargreaves

In full-year financials, AstraZeneca announced that its R&D arm, MedImmune, will be absorbed into the overall company as it restructures its R&D units into specific therapy areas.

Pharma appointments create controversy

Hired and Retired: Controversies at the top

By Ben Hargreaves

The new year has led to a new look to executive boards across the pharma industry, but the movement has arrived with a degree of intrigue in some cases.

The approval will open doors for Biocon in more than 15 European countries. (Image: iStock)

Biocon receives first generic approval in EU

By Melissa Fassbender

Biocon, an Indian biopharmaceuticals company, has received European approvals for its Rosuvastatin Calcium, a generic equivalent of AstraZeneca’s Crestor tablets.

Actavis welcomes AZ in boosting its LAMA/LABA

Actavis welcomes AZ in boosting its LAMA/LABA

By Dan Stanton

Actavis says it is excited to partner with AstraZeneca over its long-acting muscarinic antagonist/beta-agonist (LAMA/LABA) fixed dose combination respiratory drug following the latter’s acquisition of Almirall.

AZ picks Sinequa to index millions of R&D docs

AZ picks Sinequa to index millions of R&D docs

By Fiona BARRY

AstraZeneca has chosen big data and analytics services provider Sinequa, to index millions of R&D documents for use in a search platform providing “sub-second” answers to research questions.  

(Picture credit: flickr/Evinella)

Fifth major deal for Unilife injectables

By Fiona Barry

Injectable device manufacturer Unilife has announced a contract with a pharmaceutical multinational for the use of its Ocu-ject eye syringe, marking its fifth major contract in four months.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All